BioSpace News Archive

Athira Pharma, Inc. announced that it will host a webinar event with key opinion leaders to discuss the unmet medical need and the potential opportunity for fosgonimeton to improve cognition and function in mild-to-moderate Alzheimer’s disease.

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501.

Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.

Vivos Therapeutics, Inc. announced the execution of a strategic marketing and distribution alliance with an operator of multiple sleep testing and treatment centers in Colorado.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity.

Accuray Incorporated announced that the registration dossier for the Accuray Precision® Treatment Planning System has been approved by the Chinese National Medical Products Administration.

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024.

Crossject announces the appointment of the experienced life sciences executive and medical affairs and clinical research specialist Dan Chiche, MD as Chief Medical Officer North America.

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it has raised $100 million in Series E financing, led by Alerce Medical Technology Partners.